公开(公告)号：EP0173145A3

公开(公告)日：1986-03-19

申请号：EP85110007

申请日：1985-08-08

申请人： ISTITUTO FARMACOLOGICO SERONO SpA

发明人： Borrelli, Francesco ,  Antonetti, Francesco ,  Martelli, Fabrizio

IPC分类号： A61K37/14 ,  A61K31/70

CPC分类号： A61K38/446 ,  Y10S514/922 ,  A61K31/70 ,  A61K2300/00

摘要： The invention is directed to products containing an anthraquinone drug and orgotein as a combined preparation for simultaneous, separate or sequential use in cytostatic therapy and the use of orgotein for the manufacture of a medicament for reducing the toxic effects caused by anthraquinone drugs.

公开(公告)号：EP0025686B1

公开(公告)日：1984-07-11

申请号：EP80303153.3

申请日：1980-09-09

申请人： BEECHAM GROUP PLC

发明人： Davis, Adrian Francis

IPC分类号： A61K9/22 ,  A61K9/24 ,  A61K9/52 ,  A61K31/165

CPC分类号： A61K9/5084 ,  A61K31/375 ,  Y10S514/922 ,  A61K31/165

公开(公告)号：EP1439839B8

公开(公告)日：2010-09-01

申请号：EP02732758.4

申请日：2002-03-15

申请人： Aventis Pharma S.A.

发明人： BISSERY, Marie-Christine

IPC分类号： A61K31/4745 ,  A61P35/00 ,  A61K31/47 ,  A61K31/138

CPC分类号： A61K45/06 ,  A61K31/09 ,  A61K31/135 ,  A61K31/16 ,  A61K31/165 ,  A61K31/337 ,  A61K31/47 ,  A61K31/4745 ,  A61K31/70 ,  A61K31/7072 ,  Y10S514/922 ,  A61K33/24 ,  A61K31/704 ,  A61K31/475 ,  A61K31/335 ,  A61K2300/00

摘要： An antitumor combination containing a stilbene derivative and an anticancer compound chosen from taxanes, alkylating agents, antimetabolites, vinca alkaloids, epidophylloptoxins, and antibiotics as the active ingredients is provided. There are also provided methods of using these pharmaceutical preparations for the treatment of solid carcinomas and the like.

公开(公告)号：EP1327453B1

公开(公告)日：2008-05-28

申请号：EP02079059.8

申请日：2002-09-26

申请人： ED. GEISTLICH SÖHNE AG FÜR CHEMISCHE INDUSTRIE

发明人： Pfirrmann, Rolf W.

IPC分类号： A61K47/32 ,  A61K47/02 ,  A61K9/08 ,  A61K31/549

CPC分类号： A61K9/0019 ,  A61K9/08 ,  A61K31/185 ,  A61K31/54 ,  A61K31/549 ,  A61K33/14 ,  A61K47/02 ,  A61K47/183 ,  A61K47/32 ,  Y10S514/922 ,  Y10S514/97 ,  A61K2300/00

公开(公告)号：EP1810684A2

公开(公告)日：2007-07-25

申请号：EP07106823.3

申请日：2002-02-20

申请人： Nobel Limited Liability Company ,  Shipov, Valery Pavlovich

发明人： SHIPOV, Valery Pavlovich ,  TROFIMOV, Valery Afanasievich DI ,  PIGAREV, Evgeny Sergeevich ,  POPOV, Aleksandr Ivanovich ,  IVANOV, Viktor Nikolaevich

IPC分类号： A61K35/10 ,  A61K33/24 ,  A61K33/14 ,  A61P35/00

CPC分类号： A61K33/14 ,  A61K33/24 ,  A61K35/10 ,  Y10S514/922 ,  A61K2300/00

摘要： An anticancer agent containing platinum preparation, humic substances, water and sodium chloride.
Potassium tetrachloroplatinate is used as a platinum compound and lignohumic acid ammonium salts are used as humic substances taken in the following ratio of components per 1 ml of solution:

摘要翻译： 含铂制剂，腐殖质，水和氯化钠的抗癌剂。 使用四氯铂酸钾作为铂化合物，使用木质素酸铵盐作为每1ml溶液中下列组分比例的腐殖物质：

公开(公告)号：EP1051168B1

公开(公告)日：2006-03-01

申请号：EP98942013.8

申请日：1998-08-07

申请人： Duke University

发明人： DUHAYLONGSOD, Francis, G.

IPC分类号： A61K31/27 ,  A61P9/00

CPC分类号： A61K31/27 ,  A61K31/00 ,  A61K31/22 ,  A61K31/445 ,  A61K45/06 ,  A61M2210/125 ,  Y10S514/922 ,  A61K2300/00 ,  A61K31/135

摘要： Methods are provided for conducting surgical procedures in a patient wherein, during the surgical procedure, autonomous ventricular electrical conductivity and escape beats are reversibly and transiently suppressed to facilitate the surgical procedure. Also provided are compositions which are capable of inducing ventricular asystole in a patient. The compositions may include an AV node blocker. In one embodiment, compositions including an atrioventricular (AV) node blocker and a beta -blocker are provided, wherein the beta -blocker is present in an amount sufficient to substantially reduce the amount of AV node blocker required to induce ventricular asystole in the patient. The compositions and methods may be used for inducing temporary ventricular asystole in a beating heart, and to facilitate the performance of a variety of surgical techniques, including minimally invasive microsurgical techniques. Methods for performing a surgical procedure on a human patient are provided wherein a composition capable of inducing transient reversible ventricular asystole is administered to the heart, for example by intracoronary injection. The heart then is electrically paced using an electrical pacing system, thereby to maintain the patient's blood circulation. The electrical pacing then is selectively intermittently stopped to allow ventricular asystole to occur, and the steps of the surgical or therapeutic procedure, such as suturing, are conducted during the time that the electrical pacing is intermittently stopped. The methods and compositions advantageously may be used in a range of different surgical procedures including cardiac, vascular and neurosurgical procedures.

公开(公告)号：EP1210939B1

公开(公告)日：2006-01-04

申请号：EP02002974.0

申请日：1994-03-08

申请人： Sinclair Pharmaceuticals Limited

发明人： Jones, Roger Spencer

IPC分类号： A61K31/198 ,  A61K9/20 ,  A61K31/195 ,  A61K31/167

CPC分类号： A61K9/2059 ,  A61K9/2027 ,  A61K9/2095 ,  A61K31/195 ,  A61K45/06 ,  Y10S514/823 ,  Y10S514/922 ,  A61K31/165 ,  A61K2300/00

公开(公告)号：EP1518854A1

公开(公告)日：2005-03-30

申请号：EP04030121.0

申请日：1995-07-31

申请人： THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services ,  ARCH DEVELOPMENT CORPORATION ,  THE PENN STATE RESEARCH FOUNDATION, INC.

发明人： The designation of the inventor has not yet been filed

IPC分类号： C07D239/46 ,  C07D239/48 ,  C07D239/50 ,  C07D251/52 ,  C07D473/06 ,  C07D473/18 ,  C07D473/40 ,  C07D487/04 ,  A61K31/52 ,  A61K31/505 ,  A61K31/519 ,  A61P35/00

CPC分类号： C07D239/47 ,  C07D239/48 ,  C07D239/50 ,  C07D251/52 ,  C07D473/06 ,  C07D473/18 ,  C07D473/40 ,  C07D487/04 ,  Y10S514/922

摘要： The present invention provides AGT inactivating compounds such as 7- or 9-substituted 8- aza- O 6 -benzylguanines of formula (III) or (IV), and related substituted O 6 -benzyl guanines, as well as pharmaceutical compositions comprising such compounds along with a pharmaceutically acceptable carrier. The present invention further provides a method of enhancing the chemotherapeutic treatment of tumour cells in a mammal with an antineoplastic alkylating agent which causes cytotoxic lesions at the O 6 - position of guanine, by administering to a mammal an effective amount of one of the aforesaid compounds, 2,4-diamino-6-benzyloxy-s-triazine, or 8-aza-O 6 -benzylguanine, and administering to the mammal an effective amount of an antineoplastic alkylating agent which causes cytotoxic lesions at the O 6 - position of guanine.

摘要翻译： 本发明提供AGT灭活化合物，例如式（III）或（IV）的7-或9-取代的8-氮杂-O 6 - 苄基胍和相关的取代的O 6 - 鸟嘌呤，以及药物 包含这些化合物以及药学上可接受的载体的组合物。 本发明进一步提供了一种增强哺乳动物肿瘤细胞化学治疗的方法，其中抗肿瘤烷化剂通过向哺乳动物施用有效量的鸟嘌呤的有效量之一，其引起鸟嘌呤的O 6位上的细胞毒性病变 上述化合物，2,4-二氨基-6-苄氧基-s-三嗪或8-氮杂-O 6 - 苄基鸟嘌呤，并向哺乳动物施用有效量的抗肿瘤烷化剂，其在O < 6> - 鸟嘌呤的位置。

公开(公告)号：EP1494677A1

公开(公告)日：2005-01-12

申请号：EP03745238.0

申请日：2003-03-28

申请人： Institut de Cardiologie de Montreal

发明人： JUNEAU, Martin ,  TANGUAY, Jean-François ,  BROUILLETTE, Denis

IPC分类号： A61K31/5415 ,  A61P9/02 ,  A61P39/02

CPC分类号： A61K45/06 ,  A61K31/00 ,  A61K31/519 ,  A61K31/5415 ,  Y10S514/823 ,  Y10S514/921 ,  Y10S514/922 ,  A61K2300/00

摘要： The present invention relates to the use of the dye methylene blue (MB) or a related compound to prevent or reverse an exaggerated hemodynamic reaction in animals in need thereof, including humans. More specifically, the present invention concerns the use of MB or a related compound to prevent or reverse hypotension, unstable angina, myocardial infarction or shock caused by the concomitant ingestion of a phosphodiesterase inhibitor, such as sildenafil citrate, and a NO-donor, such as L-arginine, or an organic nitrate, such as nitroglycerin.

公开(公告)号：EP1441733A1

公开(公告)日：2004-08-04

申请号：EP02771956.6

申请日：2002-11-04

申请人： Shire BioChem Inc.

发明人： JOLIVET, Jacques ,  GILES, Francis J.,Department of Leukemia ,  KANTARJIAN, Hagop,Department of Leukemia

IPC分类号： A61K31/506 ,  A61P35/02

CPC分类号： A61K31/506 ,  Y10S514/908 ,  Y10S514/922

摘要： The present invention provides a novel method for treating leukemia in a host that has been previously treated with a BrcAbl tyrosine kinase inhibitor comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from H, monophosphate, diphosphate, triphosphate, carbonyl substituted with. a C1-5 alkyl, C1-5 alkenyl, C1-5 alkynyl, C5-10 aryl, and and wherein each. Rc is independently selected from the group comprising H, C1-5, alkyl, C1-5 alkenyl, C1-5.alkynyl an hydroxy protecting group